FierceBiotech Radio: #FierceMadness and a peek into the drug-naming process

drug names bracket FPMK
Be sure to download a bracket, fill it out and tweet it @FierceBiotech and @FiercePharma to get in on the fun!

FierceBiotech's Amirah Al Idrus sits down with FiercePharma's Carly Helfand and Beth Snyder Bulik to discuss this year's #FierceMadness drug-name tournament. Which names are strong contenders? Which names evoke unappealing images? And, ultimately, which name will be the last one standing?

We also chat with Scott Piergrossi, vice president of creative development at Brand Institute, a branding and identity development company that worked on more than 80% of the drug names the FDA approved in 2017.

Check out the #FierceMadness matchups and download a bracket here. And download the episode on iTunes or Stitcher, or listen below—and be sure to subscribe. Let us know what you think by leaving a review or dropping us a line at [email protected].

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

 

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.